An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
Sponsor study identifier
interventional
450
0 countries
N/A
Study Start
October 2002
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
July 2004
Actual (reported)This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2004
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2002
Date type not reportedThis date has not been verified as actual or estimated.
July 2004
Actual (reported)November 12, 2004
Actual (reported)November 15, 2004
Actual (reported)First Submitted
November 12, 2004
First Posted
November 15, 2004
Study Start
October 2002
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
July 2004
Actual (reported)Contact the study team to confirm eligibility.
Last Updated
March 20, 2014
Record last verified: 2014-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: